U.S., Nov. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07225543) titled '2-HOBA in Systemic Lupus Erythematosus' on Nov. 04.
Brief Summary: This is a phase II randomized, placebo-controlled, double-blind, cross-over study to determine the effect of isolevuglandin (IsoLG) scavenging by 2-HOBA on blood pressure and immune activation in patients with SLE. 42 patients with stable SLE will be randomized to treatment sequence to receive placebo or 750mg 2-HOBA three times a day for 4 weeks followed by a 4 week washout and then 4 weeks of the other agent.
Primary outcome measures include change in 24-hour blood pressure and NETosis. This study will provide mechanistic information on the role of IsoLGs in autoim...